< Back to previous page
Researcher
Toon Van Gorp
- Disciplines:Cancer diagnosis, Cancer therapy, Oncological surgery, Cancer biology
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Oct 2019 → 30 Sep 2022
Projects
1 - 4 of 4
- PPP2R1A as a new biomarker in type-II endometrial cancers.From1 Jan 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Predictive genetic markers for targeted therapy in gynaecological cancers: bridging the gap between “one-size-fits-all” and personalized treatmentFrom8 Oct 2020 → 30 Sep 2022Funding: BOF - projects
- Predictive genetic markers in gynaecological cancers: how to improve targeted therapy.From1 Oct 2020 → TodayFunding: FWO fundamental clinical research fellowship
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → TodayFunding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 110
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.(2023)
Authors: Toon Van Gorp
Pages: 2436 - 2445 - CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study(2023)
Authors: Diether Lambrechts, Liselore Loverix, Toon Van Gorp, Ignace Vergote
Pages: 697 - 713 - Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery(2023)
Authors: Toon Van Gorp
Pages: 68 - 75 - A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)(2022)
Authors: Toon Van Gorp
Pages: 3952 - 3964 - Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor alpha (FR alpha)-positive cancer(2022)
Authors: Toon Van Gorp
Pages: S822 - S823 - Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)(2022)
Authors: Toon Van Gorp
Pages: S786 - S786 - Relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study(2022)
Authors: Toon Van Gorp
Pages: S793 - S793 - Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor alpha (FR alpha)-positive cancer(2022)
Authors: Toon Van Gorp
Pages: S817 - S817 - Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.(2022)
Authors: Toon Van Gorp
- Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FR alpha) expression: Characterization of antitumor activity in the SORAYA study.(2022)
Authors: Toon Van Gorp